Caron A. Jacobson

22.9k total citations
215 papers, 3.8k citations indexed

About

Caron A. Jacobson is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Caron A. Jacobson has authored 215 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 189 papers in Oncology, 71 papers in Pathology and Forensic Medicine and 63 papers in Immunology. Recurrent topics in Caron A. Jacobson's work include CAR-T cell therapy research (171 papers), Lymphoma Diagnosis and Treatment (71 papers) and Biosimilars and Bioanalytical Methods (40 papers). Caron A. Jacobson is often cited by papers focused on CAR-T cell therapy research (171 papers), Lymphoma Diagnosis and Treatment (71 papers) and Biosimilars and Bioanalytical Methods (40 papers). Caron A. Jacobson collaborates with scholars based in United States, France and Netherlands. Caron A. Jacobson's co-authors include Bradley D. Hunter, Ann S. LaCasce, Frederick L. Locke, Philippe Armand, David B. Miklos, John M. Rossi, Sattva S. Neelapu, David C. Fisher, Matthew S. Davids and Jennifer R. Brown and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Caron A. Jacobson

196 papers receiving 3.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Caron A. Jacobson United States 32 2.6k 1.2k 835 790 762 215 3.8k
Sunita D. Nasta United States 29 3.3k 1.2× 1.7k 1.4× 979 1.2× 876 1.1× 695 0.9× 179 4.7k
Sindhu Cherian United States 20 3.0k 1.2× 481 0.4× 834 1.0× 853 1.1× 369 0.5× 59 3.8k
Joseph P. McGuirk United States 30 1.7k 0.6× 281 0.2× 728 0.9× 1.1k 1.4× 798 1.0× 274 3.7k
Scott R. Solomon United States 34 1.8k 0.7× 476 0.4× 1.2k 1.5× 807 1.0× 453 0.6× 197 4.2k
Aaron P. Rapoport United States 32 2.1k 0.8× 491 0.4× 703 0.8× 1.2k 1.5× 311 0.4× 162 3.8k
Brian T. Hill United States 27 1.2k 0.4× 962 0.8× 475 0.6× 746 0.9× 790 1.0× 225 2.7k
Saar Gill United States 39 4.4k 1.7× 475 0.4× 3.0k 3.7× 2.0k 2.5× 455 0.6× 174 6.9k
Sarah Nikiforow United States 31 1.8k 0.7× 282 0.2× 1.4k 1.7× 463 0.6× 354 0.5× 152 3.4k
Jennifer N. Brudno United States 19 2.9k 1.1× 204 0.2× 928 1.1× 1.0k 1.3× 153 0.2× 28 3.5k
Alison Gulbis United States 15 1.9k 0.7× 161 0.1× 826 1.0× 439 0.6× 139 0.2× 72 2.6k

Countries citing papers authored by Caron A. Jacobson

Since Specialization
Citations

This map shows the geographic impact of Caron A. Jacobson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caron A. Jacobson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caron A. Jacobson more than expected).

Fields of papers citing papers by Caron A. Jacobson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caron A. Jacobson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caron A. Jacobson. The network helps show where Caron A. Jacobson may publish in the future.

Co-authorship network of co-authors of Caron A. Jacobson

This figure shows the co-authorship network connecting the top 25 collaborators of Caron A. Jacobson. A scholar is included among the top collaborators of Caron A. Jacobson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caron A. Jacobson. Caron A. Jacobson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Landsburg, Daniel J., Matthew J. Frigault, S.R. Foley, et al.. (2025). Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. Journal for ImmunoTherapy of Cancer. 13(2). e009890–e009890. 3 indexed citations
2.
Jacobson, Caron A., Jason R. Westin, David B. Miklos, et al.. (2025). Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial. Clinical Cancer Research. 32(5). 894–904.
3.
Locke, Frederick L., Sattva S. Neelapu, Nancy L. Bartlett, et al.. (2024). Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma. Transplantation and Cellular Therapy. 30(11). 1065–1079. 13 indexed citations
4.
Ghobadi, Armin, Javier Muñoz, Jason R. Westin, et al.. (2024). Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood Advances. 8(11). 2982–2990. 4 indexed citations
5.
Oluwole, Olalekan O., et al.. (2024). Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United States. Value in Health. 27(8). 1030–1038. 1 indexed citations
6.
Nayak, Lakshmi, Ugonma Chukwueke, Christopher Meehan, et al.. (2024). A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL).. Journal of Clinical Oncology. 42(16_suppl). 2006–2006. 9 indexed citations
7.
Sureda, Anna, Pieternella J. Lugtenburg, Marie José Kersten, et al.. (2023). Cellular therapy in lymphoma. Hematological Oncology. 42(6). e3200–e3200. 3 indexed citations
8.
Ghobadi, Armin, Javier Muñoz, Jason R. Westin, et al.. (2023). Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) Zuma-7 Study. Transplantation and Cellular Therapy. 29(2). S371–S372. 1 indexed citations
9.
Ababneh, Hazim, Andrea K. Ng, Matthew J. Frigault, et al.. (2023). Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy. Haematologica. 108(11). 2972–2981. 9 indexed citations
10.
Qualls, David & Caron A. Jacobson. (2023). Comorbidities in DLBCL: too "Severe4" CAR-T therapy?. Blood Advances. 7(14). 3469–3471. 1 indexed citations
11.
Westin, Jason R., Caron A. Jacobson, Julio C. Chávez, et al.. (2023). PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA. HemaSphere. 7(S3). e3278692–e3278692. 1 indexed citations
12.
Ghione, Paola, M. Lia Palomba, Anik R. Patel, et al.. (2022). Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood. 140(8). 851–860. 35 indexed citations
13.
14.
Maurer, Katie, Haesook T. Kim, Utkarsh Acharya, et al.. (2021). COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Advances. 5(3). 861–871. 24 indexed citations
15.
Gopal, Ajay K., Ronald Levy, Roch Houot, et al.. (2020). First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clinical Cancer Research. 26(11). 2524–2534. 45 indexed citations
16.
Gupta, Shruti, Harish Seethapathy, Ian A. Strohbehn, et al.. (2020). Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. American Journal of Kidney Diseases. 76(1). 63–71. 80 indexed citations
17.
18.
19.
Lampson, Benjamin L., Haesook T. Kim, Matthew S. Davids, et al.. (2017). Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia. Blood. 130. 1734–1734. 4 indexed citations
20.
Lampson, Benjamin L., Siddha Kasar, Tiago R. Matos, et al.. (2016). Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 128(2). 195–203. 227 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sunita D. Nasta Breakdown of academic impact, for papers by Sindhu Cherian Breakdown of academic impact, for papers by Joseph P. McGuirk Breakdown of academic impact, for papers by Scott R. Solomon Breakdown of academic impact, for papers by Aaron P. Rapoport Breakdown of academic impact, for papers by Brian T. Hill Breakdown of academic impact, for papers by Saar Gill Breakdown of academic impact, for papers by Sarah Nikiforow Breakdown of academic impact, for papers by Jennifer N. Brudno Breakdown of academic impact, for papers by Alison Gulbis
Rankless by CCL
2026